Mammography screening in women aged 39–49 years: Updated randomized evidence and implications for screening policy
Cancer Epidemiology · 2026-08 · 103 · 103145
DOI: 10.1016/j.canep.2026.103145 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Epidemiology, 2026-08. Verfasst von Pedro C Abrahão Reis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address: pedroreis@ufrj.br. Hauptthemen laut MEDLINE: Mammography, Breast Neoplasms, Early Detection of Cancer, Mass Screening. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
OBJECTIVE: Mammography screening in women aged 39-49 remains controversial despite evolving guidelines. This study aimed to provide an updated synthesis of randomized clinical trials (RCTs) evaluating the effect of mammography screening on breast cancer (BC) mortality in this group. METHODS: We searched PubMed, Cochrane, and Embase for RCTs assessing the impact of mammography screening on BC mortality in women aged 39-49 years. Data extraction incorporated the most recent follow-up available. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Heterogeneity was evaluated using the I² statistic. Leave-one-out sensitivity analyses were performed to assess robustness. RESULTS: Of 797 records identified, 10 RCTs met the inclusion criteria, encompassing 163,611 women in screening arms and 206,244 in control arms. Median follow-up ranged from 14 to 30 years. The pooled RR for BC mortality was 0.89 (95% CI 0.79-1.01; p = 0.07; I²=24.3%). Exclusion of the CNBSS was the only single-trial omission that yielded a statistically significant reduction in BC mortality with mammography screening (RR 0.85; 95% CI 0.76-0.95; p = 0.005; I²=1.4%). CONCLUSIONS: These findings highlight the need for cautious interpretation of historical randomized evidence when informing screening recommendations for women aged 39-49 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address: pedroreis@ufrj.br.
- Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
- Universidade Federal do Ceará, Fortaleza, Brazil.
- Shri Sathya Sai Medical College and Research Institute, Chennai, India.
- Department of Oncology Queen's University, Kingston, ON, Canada.
- A.C. Camargo Cancer Center, São Paulo, Brazil.
Zitieren
APA
Reis, P. C. A., Oliveira, J. P., Noronha, M. M., Vellaichamy, S., Braga, M., Moraes, F. Y., Cagnacci, R., & de Liz, C. D. (2026). Mammography screening in women aged 39–49 years: Updated randomized evidence and implications for screening policy. Cancer Epidemiology, 103, 103145. https://doi.org/10.1016/j.canep.2026.103145
Vancouver
Reis PCA, Oliveira JP, Noronha MM, Vellaichamy S, Braga M, Moraes FY, et al. Mammography screening in women aged 39–49 years: Updated randomized evidence and implications for screening policy. Cancer Epidemiology. 2026;103:103145. doi:10.1016/j.canep.2026.103145
BibTeX
@article{Reis2026,
author = {Reis, Pedro C Abrahão and Oliveira, João Pedro and Noronha, Mariana Macambira and Vellaichamy, Swathi and Braga, Marcelo and Moraes, Fabio Y and Cagnacci, Renato and de Liz, Caio Dabbous},
title = {Mammography screening in women aged 39–49 years: Updated randomized evidence and implications for screening policy},
journal = {Cancer Epidemiology},
year = {2026},
volume = {103},
pages = {103145},
doi = {10.1016/j.canep.2026.103145}
}
EUVIMED